INDIANAPOLIS , July 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas ...
INDIANAPOLIS , July 22, 2026 /PRNewswire/ -- (SIX: RO, ROP; OTCQX: RHHBY) As clinical laboratories face ongoing staffing shortages and increasingly complex workflows, Roche  will showcase integrated...
INDIANAPOLIS , July 20, 2026 /PRNewswire/ -- Roche  (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective...
Priority review decision is based on Phase III MAJESTY results, where Gazyva achieved significantly higher complete remission rates at two years compared to tacrolimus ...
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.
Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib...
The filing application is based on improvements seen across key efficacy endpoints from the global Phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision)...
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.